Zhou X, Zhao Y, Li Y, Yuan Y, Yan X, Zhang W
Front Med (Lausanne). 2025; 12:1541510.
PMID: 39975669
PMC: 11836033.
DOI: 10.3389/fmed.2025.1541510.
Kanack A, Prodoehl E, Ishihara-Aoki M, Aoki K, Dahms N
Sci Rep. 2024; 14(1):29488.
PMID: 39604471
PMC: 11603304.
DOI: 10.1038/s41598-024-80633-6.
Batta G, Vishnuprasad R, Batta A, Santhanalakshmi D, Dwivedi A
Int J Appl Basic Med Res. 2024; 14(3):187-192.
PMID: 39310077
PMC: 11412568.
DOI: 10.4103/ijabmr.ijabmr_161_24.
Wallace E, Goker-Alpan O, Wilcox W, Holida M, Bernat J, Longo N
J Med Genet. 2023; 61(6):520-530.
PMID: 37940383
PMC: 11137442.
DOI: 10.1136/jmg-2023-109445.
Tsai T, Wang C, Chiang S, Huang J, Bau D, Huang Y
In Vivo. 2023; 37(6):2609-2617.
PMID: 37905636
PMC: 10621449.
DOI: 10.21873/invivo.13368.
Treatment of Fabry Nephropathy: A Literature Review.
Shimohata H, Yamashita M, Yamada K, Hirayama K, Kobayashi M
Medicina (Kaunas). 2023; 59(8).
PMID: 37629768
PMC: 10456687.
DOI: 10.3390/medicina59081478.
The evolution of the initial manifestations and renal involvement of chinese patients with classical and late-onset Fabry disease at different sexes and ages.
Guo W, Xie Y, Ji P, Li S, Cai G, Chen X
BMC Nephrol. 2023; 24(1):90.
PMID: 37020293
PMC: 10074707.
DOI: 10.1186/s12882-023-03138-w.
Long-term follow-up of renal function in patients treated with migalastat for Fabry disease.
Bichet D, Torra R, Wallace E, Hughes D, Giugliani R, Skuban N
Mol Genet Metab Rep. 2021; 28:100786.
PMID: 34401344
PMC: 8353473.
DOI: 10.1016/j.ymgmr.2021.100786.
Platelet and myeloid cell phenotypes in a rat model of Fabry disease.
Kanack A, Aoki K, Tiemeyer M, Dahms N
FASEB J. 2021; 35(8):e21818.
PMID: 34320241
PMC: 8341388.
DOI: 10.1096/fj.202001727RR.
Fabry disease: what the cardiologist should consider in non-cardiac screening, diagnosis, and management-narrative review.
Regenbogen C, Braunisch M, Schmaderer C, Heemann U
Cardiovasc Diagn Ther. 2021; 11(2):661-671.
PMID: 33968643
PMC: 8102250.
DOI: 10.21037/cdt-20-845.
Renal Manifestations of Fabry Disease: A Narrative Review.
Silva C, Moura-Neto J, Dos Reis M, Neto O, Barreto F
Can J Kidney Health Dis. 2021; 8:2054358120985627.
PMID: 33786192
PMC: 7960898.
DOI: 10.1177/2054358120985627.
Deficiency in the Screening Process of Fabry Disease: Analysis of Chronic Kidney Patients Not on Dialysis.
Battaglia Y, Fiorini F, Azzini C, Esposito P, De Vito A, Granata A
Front Med (Lausanne). 2021; 8:640876.
PMID: 33634157
PMC: 7900152.
DOI: 10.3389/fmed.2021.640876.
Variable clinical features of patients with Fabry disease and outcome of enzyme replacement therapy.
Dutra-Clarke M, Tapia D, Curtin E, Runger D, Lee G, Lakatos A
Mol Genet Metab Rep. 2021; 26:100700.
PMID: 33437642
PMC: 7788237.
DOI: 10.1016/j.ymgmr.2020.100700.
An Atypical Cardiac Manifestation of Fabry Disease from a Novel Pathological Variant on the GLA Gene.
Sarsam L, Arouni A, Mahfood Haddad T, Onaiwu C, Erickson C
Cureus. 2020; 12(3):e7262.
PMID: 32292674
PMC: 7153810.
DOI: 10.7759/cureus.7262.
Variable phenotypic presentations of renal involvement in Fabry disease: a case series.
McCloskey S, Brennan P, Sayer J
F1000Res. 2018; 7:356.
PMID: 29770213
PMC: 5930549.
DOI: 10.12688/f1000research.13708.1.
Long-term outcomes with agalsidase alfa enzyme replacement therapy: Analysis using deconstructed composite events.
Beck M, Hughes D, Kampmann C, Pintos-Morell G, Ramaswami U, West M
Mol Genet Metab Rep. 2017; 14:31-35.
PMID: 29159077
PMC: 5684503.
DOI: 10.1016/j.ymgmr.2017.10.008.
Redefining the Pulvinar Sign in Fabry Disease.
Cocozza S, Russo C, Pisani A, Olivo G, Riccio E, Cervo A
AJNR Am J Neuroradiol. 2017; 38(12):2264-2269.
PMID: 29051208
PMC: 7963734.
DOI: 10.3174/ajnr.A5420.
Ultrastructural deposits appearing as "zebra bodies" in renal biopsy: Fabry disease?- comparative case reports.
de Menezes Neves P, Machado J, Custodio F, Dos Reis Monteiro M, Iwamoto S, Freire M
BMC Nephrol. 2017; 18(1):157.
PMID: 28499424
PMC: 5427530.
DOI: 10.1186/s12882-017-0571-0.
Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis.
Beck M, Hughes D, Kampmann C, Larroque S, Mehta A, Pintos-Morell G
Mol Genet Metab Rep. 2016; 3:21-7.
PMID: 26937390
PMC: 4750577.
DOI: 10.1016/j.ymgmr.2015.02.002.
Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch-2-Year Follow-Up.
Lenders M, Canaan-Kuhl S, Kramer J, Duning T, Reiermann S, Sommer C
J Am Soc Nephrol. 2015; 27(3):952-62.
PMID: 26185201
PMC: 4769208.
DOI: 10.1681/ASN.2015030337.
